DOWNSTREAM PROCESSING FEATURED ARTICLES
GE Healthcare Launches ÄKTA™ Pure, A New Modular Chromatography System For Protein Purification
GE Healthcare, the healthcare business of GE announced recently the launch of ÄKTA™ pure, a chromatography system for flexible, reliable and intuitive purification of proteins.
-
Crucell And Scripps Research Discover And Describe Broad-Spectrum Antibodies Against Influenza B, A Crucial Link In Development Of Universal Flu Therapies And Vaccine
In a landmark discovery, researchers from Crucell Holland B.V. and The Scripps Research Institute, recently announced the identification of the first human monoclonal antibodies that appear capable of disabling all influenza B viruses.
-
CellCentric And ZoBio Enter Into Partnership To Develop Lead Compounds Against Epigenetic Drug Targets
ZoBio and CellCentric are pleased to announce that the companies are working together to discover lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets. ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric. Hit to lead and lead optimisation activities will be further supported by ZoBio’s biophysical and medicinal chemistry research services.
-
FDA Reports Conditions Observed At New England Compounding Center Facility
Recently, the U.S. Food and Drug Administration released a copy of the FDA Form 483 issued to the New England Compounding Center (NECC). The FDA observed and has since confirmed contaminated products and listed a number of observations regarding conditions in the clean room at NECC’s Framingham, Mass. facility.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Best Practices For Process Scale Column Packing Of CHT™ Ceramic Hydroxyapatite Media
CHT ceramic hydroxyapatite media require specific considerations during process-scale chromatography packing due to high specific gravity, rapid settling rate, and sensitivity to mechanical shear.
-
Compound Profiling And Toxicity
Utilizing a systems approach to drug discovery has generated a multitude of high affinity compounds for various classes of molecular targets with different degrees of disease state validation.
-
Improving DNA Removal from Bioprocess Purification Processes
Many new biological drug products produced using recombinant DNA technology, such as monoclonal antibodies, are produced in cell culture. Because therapeutic proteins such as monoclonal antibodies are produced in cell culture, impurities can result from the host cells, or cell substrates. By 3M Purification Inc.
-
Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography Media
Monoclonal antibodies (mAbs) remain a predominant class of therapeutic protein products on the market because of their wide range of applications in disease treatment and diagnosis. Over the years, upstream technology advancements have helped improve the titer of target antibodies, from merely 1 g/L two decades ago to 10–13 g/L in fed-batch processes and up to 25 g/L in perfusion cultures today (Gronemeyer et al. 2014).
-
Efficiency Test Of ReadyToProcess™ Columns
ReadyToProcess™ columns are prepacked, prequalified, and presanitized process chromatography columns suited for purification of biopharmaceuticals (e.g., proteins, vaccines, plasmids, and viruses) for clinical phase I and II studies. ReadyToProcess columns are available with several media at different volumes (1, 2.5, 10, and 20 L).
-
Selecting The Optimal Resins For The Process Purification Of Native And Recombinant Proteins
Native and recombinant proteins are used in a variety of applications ranging from drug discovery to target validation to high-throughput screening. Due to this, large-scale protein production and purification have become major necessities in industrial settings.